MPT Product Development Database

Multipurpose Prevention Technologies (MPTs) are an innovative class of products that deliver varied combinations of HIV prevention, other STI prevention, and contraception and will improve the lives of women and families worldwide.

This database includes MPT products that are currently in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.

Click on the tables for MPT products in the development pipeline, listed by:
 
 
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
 
Hormonal/Non-HormonalDelivery RouteDelivery MethodDevelopment Stage
       
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
       
Key Word Search   
       

24 product(s) found



EVO100 Gel

MPT in Development

Development Stage:
Clinical – Phase 3 Trial (C3)
Hormonal/Non-Hormonal:
Non-Hormonal
Delivery Route & Method:
Topical - Gel-Vaginal
Mechanism of Action:
Vaginal pH regulation
Developer:
  • Evofem Biosciences, Inc.
  • Funding:
  • Evofem Biosciences, Inc.
  • Active Ingredient:
  • Citric Acid
  • L-lactic Acid
  • Potassium Bitartrate
  • Product Indications:
  • Chlamydia
  • Gonorrhea
  • Pregnancy
  • Description:
    The Phase 2b study evaluating EVO100 Gel for the prevention of chlamydia and gonorrhea met its primary and secondary endpoints, and was generally safe and well tolerated. It has been granted Fast Track Designation for the prevention of chlamydia in women and Qualified Infectious Disease Product (QIDP) Designation for the prevention of gonorrhea in women by the U.S. Food and Drug Administration (FDA). As of 2020, Phase 3 trials for the contraceptive indication are complete and has been approved in the United States by the FDA under the brand name Phexxi™.
    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825
    IMPT@cami-health.org

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    © Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.